REMUS quarterly results and annual financials: sales, operating profit, OPM, net profit, EPS, balance sheet, cash flow and ratios like ROCE, with YoY and QoQ growth.
Remus Pharmaceuticals Ltd reported sales of ₹614 Cr, operating profit of ₹30 Cr (OPM 4.9%) and net profit of ₹25 Cr for the quarter ended Sep 2026. Figures in ₹ crore, consolidated where available.
REMUS quarterly results (₹ Cr)
Metric
tooltips
Sep 2023
Mar 2024
Sep 2024
Mar 2025
Sep 2025
Mar 2026
Sep 2026
Sales
-
29
185
273
348
400
453
614
YoY Sales growth
-
-
-
839
88
47
30
53
Expenses
-
20
165
252
323
373
424
584
Operating Profit
-
9
20
20
25
27
30
30
OPM
-
32%
11%
8%
7%
7%
7%
4.9%
Other Income
-
2
3
3
3
3
4
4
Interest
-
0
0
1
1
1
1
1
Depreciation
-
0
1
0
1
1
1
2
Profit before tax
-
10
22
22
25
28
31
32
Tax
-
25%
15%
16%
19%
23%
21%
22%
Net Profit
-
6
19
19
21
22
25
25
EPS in Rs
-
4.87
13.16
11.87
13.57
14.85
16.54
18.47
REMUS profit & loss, annual (₹ Cr)
Metric
tooltips
Mar 2024
Mar 2025
Mar 2026
TTM
Sales
-
213
620
854
1,068
Sales growth
-
-
191
38
43
Expenses
-
184
575
797
1,008
Operating Profit
-
29
46
57
60
OPM
-
14%
7%
7%
6%
Other Income
-
3
5
7
8
Interest
-
0
1
1
2
Depreciation
-
1
2
3
3
Profit before tax
-
30
47
59
63
Tax
-
20%
19%
22%
-
Net Profit
-
24
38
46
49
EPS in Rs
-
17.69
24.64
31.39
35.01
Dividend Payout
-
4%
3%
2%
-
REMUS balance sheet (₹ Cr)
Metric
Mar 2024
Mar 2025
Sep 2025
Mar 2026
Sep 2026
Equity Capital
1
6
12
12
12
Reserves
156
250
295
339
524
Borrowings
14
23
16
27
25
Other Liabilities
161
154
245
201
226
Total Liabilities
333
433
568
579
788
Fixed Assets
14
16
18
18
27
CWIP
0
0
0
8
0
Investments
105
186
238
275
484
Other Assets
215
231
313
277
277
Total Assets
333
433
568
579
788
REMUS cash flows (₹ Cr)
Metric
Mar 2024
Mar 2025
Mar 2026
Cash from Operating Activity
4
7
18
Cash from Investing Activity
-9
-11
-15
Cash from Financing Activity
24
6
1
Net Cash Flow
19
2
5
Free Cash Flow
3
3
4
CFO/OP
25%
32%
-
CFO/EBITDAShare of operating profit converting into cash: CFO (before tax) / Operating Profit